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Abstract 
Objective 
 
PF-04691502 and gedatolisib (PF-05212384) are potent, dual PI3K/mTOR inhibitors. This phase II 
study (B1271004) was conducted in patients with recurrent endometrial cancer following platinum-
containing chemotherapy. The primary endpoint was to assess clinical benefit response (complete or 
partial response, or stable disease for ≥ 16 weeks) following treatment with PF-04691502 or 
gedatolisib. 
 
Methods 
 
The main study consisted of four independent arms based on a Simon two-stage design. Patients 
were assigned to putative PI3K-basal (PF-04691502 or gedatolisib) or PI3K-activated (PF-04691502 or 
gedatolisib) arms based on stathmin-low or stathmin-high tumor expression, respectively. Japanese 
patients were also enrolled in a separate lead-in cohort. 
 
Results 
 
In stage 1 (main study), eighteen patients were randomized to PF-04691502 and 40 to gedatolisib. 
The two PF-04691502 arms were discontinued early due to unacceptable toxicity, including 
pneumonia and pneumonitis. The most common treatment-related adverse events associated with 
gedatolisib were nausea (53%), mucosal inflammation (50%), decreased appetite (40%), diarrhea 
(38%), fatigue (35%), and dysgeusia and vomiting (each 30%). Clinical benefit response rate was 53% 
(10/19) in the gedatolisib/stathmin-low arm and 26% (5/19) in the gedatolisib/stathmin-high arm. 
Safety profile and pharmacokinetic characteristics of both drugs in the Japanese lead-in cohort were 
comparable to the Western population. 
 
Conclusions 
 
Gedatolisib administered by weekly intravenous infusion demonstrated acceptable tolerability and 
moderate activity in patients with recurrent endometrial cancer. PF-04691502 daily oral dosing was 
not well tolerated. Clinical benefit response criteria for proceeding to stage 2 were only met in the 
gedatolisib/stathmin-low arm. Stathmin-high expression did not correlate with greater treatment 
efficacy. 
 
ClinicalTrials.gov registration ID: NCT01420081. 
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1. Introduction 
Endometrial cancer affects an estimated 52,630 women in the United States, accounting for > 8000 
deaths each year [1]. It is the most common gynecologic malignancy, and represents ~ 6% of all 
cancers in women [1] ;  [2]. The prognosis is poor for patients with recurrent disease or Stage IV 
endometrial cancer typically treated with a platinum-containing regimen. To date, chemotherapy 
regimens or currently available targeted agents have not improved clinical outcomes for patients 
with recurrent or metastatic disease and there is no standard of care for these patients, particularly 
after platinum-based chemotherapy [3]; [4]; [5] ;  [6]. 
 
Phosphatidylinositol 3-kinases (PI3K) constitute a lipid kinase family involved in the regulation of 
diverse cellular processes, including cell proliferation [7]. Activation of the PI3K pathway has been 
implicated in a wide variety of human cancers and is prevalent in both type 1 and 2 endometrial 
cancers. Pathway aberrations can present as mutations in PIK3CA, the gene encoding the catalytic 
subunit of PI3K, and they have been observed in ~ 30% of type 1 and 20% of type 2 endometrial 
cancers [8]. 
 
Stathmin has been considered a potential marker of PI3K pathway activation in solid tumors and its 
protein expression can be assessed by immunohistochemistry (IHC) [9]; [10] ;  [11]. Salvesen and 
colleagues reported that stathmin-high correlated with a PI3K signature, 3q26.32 chromosomal 
amplification, and PI3K protein overexpression in endometrial cancer specimens [10] ;  [11]. Trovik 
and colleagues reported that stathmin is readily detectable in endometrial cancer, with high levels of 
stathmin in 35% of endometrioid cancers and 50% to 55% of non-endometrioid curettage specimens 
by IHC [9]. 
 
PF-04691502 is a potent dual inhibitor of PI3K and mTOR [TOR complex (TORC)1 and TORC2] kinase 
activity intended for once-daily oral dosing [12]. In the first-in-patient study (B1271001), 37 patients 
with advanced solid tumors received PF-04691502 at doses ranging from 2 to 11 mg daily [13]. The 
maximum tolerated dose (MTD) was determined to be 8 mg. The most frequent treatment-related 
adverse events (AEs) at the MTD were fatigue (41%), decreased appetite (35%), nausea (35%), 
hyperglycemia (27%), rash (27%), and vomiting (27%). There was one treatment-related grade 4 AE 
of hypotension (8-mg dose level). One case each of acute respiratory distress syndrome and 
pneumonitis were reported, but not considered related to study treatment [13]. 
 
Gedatolisib (PF-05212384) is a potent inhibitor of PI3K and mTOR (TORC1 and TORC2) kinase activity 
intended for once-weekly intravenous infusion [14]. The safety and pharmacokinetic profile of 
gedatolisib were initially evaluated in patients with advanced solid tumors [15]. In that initial clinical 
study, 77 patients received gedatolisib at doses ranging from 10 to 319 mg. The MTD was 
determined to be 154 mg weekly. The most frequent treatment-related AEs at the MTD were 
mucosal inflammation (43%), nausea (41%), hyperglycemia (26%), and vomiting (24%). There were 
no grade 4 or higher treatment-related AEs [15]. 
 
The purpose of this phase II study was to evaluate single-agent treatment with PF-04691502 or 
gedatolisib in Western and Japanese patients with recurrent endometrial cancer. This study also 
tested the hypothesis that elevated stathmin expression in tumors, as a biomarker of PI3K/mTOR 
pathway activation, would predict response to treatment. 
 
2. Patients and methods 
2.1. Patients 
 
Study B1271004 enrolled adult women with a confirmed diagnosis of recurrent endometrial cancer 
with disease progression following one or more platinum-containing regimen (adjuvant or 
metastatic setting). Patients also had to have at least one measurable lesion by Response Evaluation 
Criteria in Solid Tumors (RECIST) guidelines version 1.1, an Eastern Cooperative Oncology Group 
performance status of 0 or 1, and screening laboratory values within normal limits. 
 
Patients were excluded if they had active central nervous system metastases or uncontrolled 
diabetes mellitus; or had received prior treatment with PI3K-, mTOR- or AKT-targeting agents, or > 2 
prior cytotoxic chemotherapy regimens (adjuvant or metastatic setting). Patients enrolled in the 
Japanese lead-in cohort (LIC) were not required to have measurable disease per RECIST. 
 
Approval from the institutional review board or independent ethics committee of each participating 
center was required; all patients gave informed consent. The study followed the Declaration of 
Helsinki and International Conference on Harmonization Good Clinical Practice guidelines. The study 
was sponsored by Pfizer and registered at ClinicalTrials.gov (NCT01420081). 
 
2.2. Study design (main study) 
 
Study B1271004 was an open-label, randomized, phase II, four-arm, optimal Simon two-stage, non-
comparative, multicenter study designed to evaluate safety, efficacy, pharmacokinetics, and 
pharmacodynamics of PF-04691502 and gedatolisib. The planned starting doses for PF-04691502 
and gedatolisib were oral 8 mg daily and intravenous 154 mg weekly, respectively, which were the 
MTDs established for these study drugs. 
 
The primary endpoint was clinical benefit response (CBR), defined as complete response (CR), partial 
response (PR), or stable disease for ≥ 16 weeks. The study also included a separate LIC conducted at 
Japanese sites to explore safety and pharmacokinetics of each study drug in a Japanese patient 
population before including Japanese patients in the main study. 
 
Eligible patients were stratified by putative PI3K pathway activation status (e.g. PI3K basal/stathmin-
low or PI3K activated/stathmin-high status) and tumor histology (types 1 and 2), and randomly 
assigned within each stratum to receive either PF-04691502 or gedatolisib. Type 1 tumors included 
grade 1–2 endometrioid adenocarcinomas. Type 2 tumors included grade 3 endometrioid 
adenocarcinomas; serous, clear cell, and mucinous adenocarcinomas; squamous cell carcinomas; 
other mixed adenocarcinomas; and transitional, small cell, or undifferentiated carcinomas [7]. 
Putative PI3K pathway activation was characterized based on tumor stathmin expression by IHC. 
High (2 + and 3 +) stathmin expression was hypothesized to be a marker of PI3K pathway activation 
and low (1 +) expression to represent PI3K basal activity. 
 
Stage 1 analysis for CBR and additional DNA- and protein-based biomarkers of PI3K pathway 
activation (e.g. PIK3CA amplification, PTEN loss) were planned after 20 response-evaluable patients 
had been enrolled and were assessable for CBR in each study arm. 
 
2.3. Study design (LIC) 
 
The LIC was designed to assess the tolerability and pharmacokinetics of PF-04691502 and gedatolisib 
in Japanese patients in order to allow them to be enrolled in the main study. In the LIC, patients 
received either PF-04691502 or gedatolisib at an oral starting dose of 4 mg daily or intravenous 89 
mg weekly, respectively, which were both below the MTD established in non-Japanese patients in 
previous phase I trials (B1271001 and B2151001). Following one cycle of dosing, if no first-cycle 
unacceptable toxicity or one was observed among three patients at each dose level, the Japanese 
sites would join the main study. If two or more patients experienced unacceptable toxicity, the LIC 
would be discontinued and patients in Japan would not join the main study for that agent. 
 
Unacceptable toxicity criteria for the LIC followed the dose reduction criteria for the main study and 
included grade 4 neutropenia ≥ 7 days, febrile neutropenia, or grade 4 thrombocytopenia; grade ≥ 3 
gastrointestinal toxicity despite optimal treatment; grade ≥ 3 unmanageable hyperglycemia; mean 
corrected QT interval ≥ 500 ms; clinically significant interstitial lung disease or other respiratory 
toxicity interfering with daily living; and any other grade ≥ 3 toxicity or treatment delay of ≥ 2 weeks 
due to study drug–related toxicity. 
 
2.4. Study assessments 
 
Safety was assessed by physical examination, laboratory tests, and AE reporting. AEs were graded 
for severity using the National Cancer Institute Common Terminology Criteria for Adverse Events 
version 4.0. 
 
Tumor assessments were performed for all patients at screening, week 8, and every 8 weeks 
thereafter. Response was assessed by the investigator, based on RECIST version 1.1. PR and CR were 
confirmed by a repeat assessment after ≥ 4 weeks. 
 
All patients were required to provide an archival or fresh tumor sample for biomarker analysis 
during the screening period. Formalin-fixed paraffin-embedded (FFPE) tumor tissues were analyzed 
for stathmin and PTEN expression status, PIK3CA amplification, and KRAS mutation status. Stathmin 
and PTEN protein expression were assessed in FFPE tumor tissues using IHC staining at Quintiles Inc. 
(Marietta, GA, USA). Stathmin IHC results were evaluated by a pathologist in central review and 
reported as H-scores based on staining intensity (1 +, 2 +, 3 +), by CLIA [Clinical Laboratory 
Improvement Amendments] standards. Following initial screening, samples from all enrolled 
patients were re-scored in the central laboratory according to an updated threshold. PTEN IHC 
results were analyzed and reported as a manual pathologist score (0, 1 +, 2 +, 3 +). PIK3CA gene was 
detected in FFPE tissues using a fluorescence in situ hybridization (FISH) assay at Quintiles Inc. The 
total number of PIK3CA gene copies was analyzed. A score > 2.2 was considered amplified. KRAS 
mutation analysis was performed using the Qiagen KRAS RGQ PCR assay (Qiagen, Manchester, UK), 
able to detect seven different KRAS single-nucleotide polymorphism mutations (G12A, G12D, G12R, 
G12C, G12S, G12V, and G13D) in DNA from FFPE tissue samples. Further biomarker analyses will be 
published in a future manuscript. 
 
Blood was collected for pharmacokinetic sampling of gedatolisib on day 1 of cycle 1 at 0 h (pre-dose) 
and at 0.5 (after end of infusion), 1, 2, 4, 6, 24, 72, and 120 h; and pre-dose on day 1 of subsequent 
cycles, through cycle 4. Plasma samples were analyzed for gedatolisib concentrations at inVentiv 
Health Clinical, Inc. (Princeton, NJ, USA) using a validated analytical assay. 
 
2.5. Statistical analyses 
 
The optimal Simon two-stage design based on CBR was used for each of the four arms 
independently. For each arm, the study tested the null hypothesis, with a one-sided 10% significance 
level, that the CBR rate was ≤ 35% versus the alternative hypothesis that the CBR rate was ≥ 50%. 
Fifty-eight response-evaluable patients were required in each study arm to provide 80% power to 
reject the null hypothesis when the true response rate was 50%. Further details on progression to 
stage 2 are provided in Supplementary Text. The CBR rate was calculated as the proportion of 
patients with confirmed CR, PR, or stable disease for ≥ 16 weeks (from day 1 of cycle 1 to treatment 
failure) relative to the total number of response-evaluable patients. 
 
Secondary efficacy endpoints included objective response rate (ORR), defined as the proportion of 
patients with CR and PR; progression-free survival (PFS); and overall survival. Due to early study 
termination, survival follow-up was discontinued. Response rates were presented with 95% 
confidence intervals (CIs). Time-to-event endpoints were analyzed using the Kaplan–Meier method; 
median values and corresponding 95% CIs were calculated. PFS was calculated from administration 
of first study drug dose to first documentation of recurrence/progression or death due to any cause. 
 
3. Results 
3.1. Patients (main study) 
 
A total of 58 patients with recurrent endometrial cancer were enrolled. Fourteen patients received 8 
mg and four patients received 6 mg as the starting oral dose of PF-04691502. Forty patients received 
154 mg weekly as the starting intravenous dose of gedatolisib. Thirty-eight patients treated with 
gedatolisib and 15 treated with PF-04691502 were evaluable for efficacy (Fig. 1). Patient baseline 
demographic and disease characteristics are shown in Table 1. 
 
Fig. 1 
Fig. 1. 
 
 
 
 
 
 
  
Flow of patients through the main study. All patients in the main study were evaluable for safety. 
One patient treated with PF-04691502 and two treated with gedatolisib were not evaluable for 
efficacy due to lack of adequate baseline assessment. Two patients treated with PF-04691502 were 
not evaluable for efficacy due to lack of measurable disease. 
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Abbreviations: ECOG PS, Eastern Cooperative Oncology Group performance status; PF-502, 
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a 
Percentages for subcategories may not add to 100% due to rounding. 
b 
One patient had received 3 prior cytotoxic chemotherapy regimens and was considered a 
protocol violation. The other patients with > 2 prior regimens had received non-cytotoxic 
agents (hormonal treatments) in prior regimens and thus they were eligible for the study. 
 
As of this analysis, all patients treated with PF-04691502 (n = 18) and 93% (n = 37) of patients 
treated with gedatolisib had discontinued study treatment. Patients discontinued PF-04,691,502 due 
to disease progression (39%), AEs (56%; e.g., treatment-related urticaria, diarrhea, pneumonia, 
pneumonitis, stomatitis, spontaneous pneumothorax, and hyperglycemia), or death (6%). Patients 
discontinued gedatolisib due to disease progression (75%) and AEs (15%; e.g. treatment-related 
fatigue, pulmonary embolism, and infusion reaction; and non-treatment-related new primary gastric 
cancer, acute renal failure, and back pain/withdrawn consent). Median treatment duration and total 
dose received are summarized for both agents in Supplementary Table S1. 
 
3.2. Safety and tolerability 
 
Treatment-related AEs of any grade observed in ≥ 20% of patients treated with PF-04691502 (n = 18) 
included diarrhea (67%); fatigue (61%); hyperglycemia (56%); nausea (56%); decreased appetite 
(39%); dry mouth, hypokalemia, mucosal inflammation, and stomatitis (each 33%); and dysgeusia, 
dyspnea, pneumonitis, and rash (each 22%). The most common grade 3–4 treatment-related AEs in 
patients treated with PF-04691502 were hyperglycemia (28%); stomatitis (22%); and diarrhea, 
pneumonia, and pneumonitis (each 17%; Table 2). Treatment-related serious AEs (SAEs) observed in 
more than one patient included grade 2–3 pneumonitis (n = 4), grade 3–4 pneumonia (n = 3), grade 
3 diarrhea (n = 3), and grade 3–4 stomatitis (n = 2). One patient experienced a grade 4 SAE of 
hyperglycemia. 
 
Table 2. 
 
Table 2. 
Treatment-related grade 3–4 AEs in ≥ 1 patient in any cohort (safety populationa). 
Event, 
n (%) 
Main study 
 
Japanese lead-in cohort 
 
PF-
502 
(put
ativ
e 
PI3
K 
bas
al) 
n = 
6 
PF-
502 
(put
ativ
e 
PI3
K 
activ
ated
) 
n = 
12 
PF-502 
(putativ
e PI3K 
activate
d + bas
al) 
n = 18 
Ged
atolis
ib 
(puta
tive 
PI3K 
basal
) 
n = 2
1 
Ged
atolis
ib 
(puta
tive 
PI3K 
activ
ated) 
n = 1
9 
Gedatoli
sib 
(putativ
e PI3K 
activate
d + bas
al) 
n = 40 
PF
-
50
2 
(4 
mg
) 
n 
= 
3 
Ged
atolis
ib 
(89 
mg) 
n = 3 
Ged
atolis
ib 
(154 
mg) 
n = 3 
Gedatoli
sib 
(89 mg 
+ 154 m
g) 
n = 6 
Any 
grade 
3/4 AE 
5 
(83) 
11 
(92) 
16 (89) 4 
(19) 
9 
(47) 
13 (33) 3 
(1
00
) 
0 1 
(33) 
1 (17) 
Asthen
ia 
0 0 0 1 (5) 1 (5) 2 (5) 0 0 0 0 
Diarrh
ea 
1 
(17) 
2 
(17) 
3 (17) 0 1 (5) 1 (3) 0 0 0 0 
Dyspn
ea 
0 2 
(17) 
2 (11) 0 0 0 0 0 0 0 
Fatigu
e 
0 2 
(17) 
2 (11) 0 4 
(21) 
4 (10) 1 
(3
3) 
0 0 0 
Hyper 0 5 5 (28) 0 0 0 0 0 0 0 
Event, 
n (%) 
Main study 
 
Japanese lead-in cohort 
 
PF-
502 
(put
ativ
e 
PI3
K 
bas
al) 
n = 
6 
PF-
502 
(put
ativ
e 
PI3
K 
activ
ated
) 
n = 
12 
PF-502 
(putativ
e PI3K 
activate
d + bas
al) 
n = 18 
Ged
atolis
ib 
(puta
tive 
PI3K 
basal
) 
n = 2
1 
Ged
atolis
ib 
(puta
tive 
PI3K 
activ
ated) 
n = 1
9 
Gedatoli
sib 
(putativ
e PI3K 
activate
d + bas
al) 
n = 40 
PF
-
50
2 
(4 
mg
) 
n 
= 
3 
Ged
atolis
ib 
(89 
mg) 
n = 3 
Ged
atolis
ib 
(154 
mg) 
n = 3 
Gedatoli
sib 
(89 mg 
+ 154 m
g) 
n = 6 
glycem
ia 
(42) 
Hypert
ension 
0 0 0 3 
(14) 
0 3 (8) 0 0 0 0 
Hypok
alemia 
1 
(17) 
1 (8) 2 (11) 0 1 (5) 1 (3) 0 0 0 0 
Pneum
onia 
1 
(17) 
2 
(17) 
3 (17) 0 0 0 1 
(3
3) 
0 0 0 
Pneum
onitis 
2 
(33) 
1 (8) 3 (17) 0 0 0 0 0 0 0 
Pulmo
nary 
emboli
sm 
0 0 0 0 2 
(11) 
2 (5) 0 0 0 0 
Rash 1 
(17) 
1 (8) 2 (11) 0 0 0 2 
(6
7) 
0 1 
(33) 
1 (17) 
Stomat
itis 
1 
(17) 
3 
(25) 
4 (22) 0 1 (5) 1 (3) 0 0 0 0 
Abbreviations: AE, adverse event; PF-502, PF-04691502; Pl3K, phosphatidylinositol 3-
kinases. 
 
 
 
 
 
Due to the high incidence of pneumonia and pneumonitis, the starting dose of PF-04691502 was 
reduced from 8 (n = 14) to 6 mg (n = 4) in August 2012, ~ 7 months after study initiation. Dose 
reductions were required in 14 (78%) patients treated with PF-04691502; two (11%) patients 
experienced a dose delay. Nine deaths occurred in patients treated with PF-04,691,502 during the 
course of the study. Of these 9 deaths, one was due to treatment-related aspiration pneumonia 
within 28 days of final dose and eight during the follow-up period were due to disease progression. 
Enrollment to the PF-04691502 study arms was stopped in October 2012, after review of safety data 
from this and another phase IB/II study (B1271003). 
 
In the gedatolisib arms (n = 40), treatment-related AEs of any grade observed in ≥ 20% of patients 
included nausea (53%), mucosal inflammation (50%), decreased appetite (40%), diarrhea (38%), 
fatigue (35%), dysgeusia and vomiting (each 30%), rash (23%), and stomatitis (20%). Asthenia, dry 
mouth, and hyperglycemia were each noted in 18% of patients. The most common grade 3–4 
treatment-related AEs in patients treated with gedatolisib were fatigue (10%), hypertension (8%), 
and asthenia and pulmonary embolism (each 5%; Table 2). Treatment-related SAEs were reported 
for three patients; the events were grade 3–4 pulmonary embolism (n = 2) and grade 2 chills (n = 1). 
 
Dose reductions were required in 24 (60%) patients treated with gedatolisib; 18 (45%) patients 
experienced a dose delay. Nineteen patients receiving gedatolisib died during the course of the 
study. Two deaths due to disease progression occurred within 28 days of final dose. Of the 17 deaths 
that occurred during the follow-up period, 16 were due to disease progression and one to other, 
unspecified reason. 
 
3.3. Antitumor activity (main study) 
 
Antitumor activity is only reported for patients treated with gedatolisib, as the PF-04691502 arms 
were stopped early for safety reasons. Best overall responses based on investigator review of 
radiographic and clinical data are summarized in Table 3. Data are presented for patients as 
randomized; however, one patient treated with gedatolisib had stathmin status changed from high 
to low after randomization, following a re-evaluation in central review of the threshold used to 
distinguish high versus low expression. 
 
Table 3. 
 
Table 3. 
Best overall response to study treatment (main study evaluable population – randomized 
treatment groupa). 
Response Gedatolisib (putative 
PI3K basal; stathmin 
low) 
n = 19 
Gedatolisib (putative 
PI3K activated; 
stathmin high) 
n = 19 
Gedatolisib (putative 
PI3K basal + activated) 
n = 38 
Objective 
responsea, n 
(%) 
3 (16) 3 (16) 6 (16) 
 95% CI 3–40 3–40 6–31 
 CR 0 1 (5) 1 (3) 
 PR 3 (16) 2 (11) 5 (13) 
Stable disease, 
n (%) 
   
 < 16 weeks 3 (16) 3 (16) 6 (16) 
 ≥ 16 weeks 7 (37) 2 (11) 9 (24) 
CBRb, n (%) 10 (53) 5 (26) 15 (40) 
 95% CI 29–76 9–51 24–57 
Progressive 
disease, n (%) 
6 (32) 8 (42) 14 (37) 
Abbreviations: CBR, clinical benefit response; CI, confidence interval; CR, complete 
response; Pl3K, phosphatidylinositol 3-kinases; PR, partial response. 
a 
Objective response includes CR and PR. 
b 
CBR includes CR, PR, and stable disease for ≥ 16 weeks. 
 
 
Overall, 15 (40%; 95% CI: 24–57%) patients treated with gedatolisib experienced CBR: 10 (53%; 95% 
CI: 29–76%) patients randomized to the gedatolisib/stathmin-low arm and five (26%; 95% CI: 9–51%) 
patients randomized to the gedatolisib/stathmin-high arm. The ORR for all gedatolisib-treated 
patients was 16% (95% CI: 6–31%); 16% (95% CI: 3–40%) for patients in the stathmin-low arm and 
16% (95% CI: 3–40%) in the stathmin-high arm, including one patient with CR. An additional 37% and 
11% of patients in the gedatolisib/stathmin-low and -high arms, respectively, achieved stable disease 
and maintained it for ≥ 16 weeks (Table 3 and Fig. 2). 
 
Fig. 2 
Fig. 2.   
Waterfall plot of best tumor response in patients treated with gedatolisib in (a) the putative PI3K-
basal/stathmin-low arm and (b) the putative PI3K-activated/stathmin-high arm (per protocol analysis 
set, randomized treatment group). Maximum change (%) = (smallest tumor size after baseline − 
baseline tumor size) / baseline tumor size. Only patients with target lesion measurements after 
baseline were included in this analysis. 
Figure options 
Median PFS was 112 (95% CI: 59–167) days and 89 (95% CI: 56–172) days in the 
gedatolisib/stathmin-low and -high arms, respectively. The overall median PFS for all patients 
treated with gedatolisib was 108 (95% CI: 62–149) days. In the gedatolisib/stathmin low arm, four of 
the 19 patients had PFS beyond 6 months ranging from 226 to 336 days. In the gedatolisib/stathmin 
high arm, four of the 19 patients had PFS beyond 6 months ranging from 220 to 404 days. 
 
3.4. Japanese LIC 
 
In the Japanese LIC, three patients received PF-04691502 4 mg daily and six patients received 
gedatolisib 89 mg (n = 3) or 154 mg (n = 3) weekly. Baseline demographic and disease characteristics 
are shown in Table 1. One patient treated with PF-04691502 discontinued treatment due to disease 
progression and two due to AEs (pneumonia and rash). All six patients treated with gedatolisib 
discontinued treatment due to disease progression or relapse (n = 5) or other, non-AE-related 
reason (n = 1). Median treatment durations are summarized for both agents in Supplementary Table 
S1. 
 
Treatment-related AEs of any grade observed in more than one patient treated with PF-04691502 (n 
= 3) included rash (n = 3), hyperglycemia (n = 2), and malaise (n = 2). Rash was the only grade 3–4 AE 
occurring in more than one patient in this group (n = 2). Treatment-related SAEs were reported in 
one patient, including Pneumocystis jirovecii pneumonia and lymphopenia. Dose reductions were 
required in all three PF-04691502-treated patients and dose delays occurred in one (33%) patient. 
No deaths occurred on study or during follow-up in patients treated with PF-04691502. 
 
Treatment-related AEs of any grade observed in more than one patient treated with gedatolisib (n = 
6) included nausea and stomatitis (n = 6 each); decreased appetite, malaise, oropharyngeal pain, 
pruritus, and rash (n = 3 each); and abdominal pain, cheilitis, conjunctivitis, paronychia, and vomiting 
(n = 2 each). Anemia and maculopapular rash were the only grade 3–4 AEs occurring in this group (n 
= 1 each). No treatment-related SAEs occurred in gedatolisib-treated patients (Table 2). Dose 
reductions were required in four of six (67%) gedatolisib-treated patients and dose delays occurred 
in four of six (67%) patients. Two deaths due to disease progression occurred during follow-up in 
patients treated with gedatolisib. 
 
Patients treated with gedatolisib in the LIC were not evaluable for efficacy, as they were not 
required to have measurable lesions. As none of the patients treated at the 89-mg dose experienced 
unacceptable toxicities and the pharmacokinetic profile of gedatolisib in the Japanese LIC was 
comparable to the Western population, three patients received the 154-mg dose. Since also the 
patients treated at 154 mg did not experience any unacceptable toxicities and had comparable 
pharmacokinetics, it was determined that Japanese patients could be randomized in the main study 
with the Western patients. 
 
3.5. Pharmacogenomics, pharmacodynamics, and pharmacokinetics 
 
Results of pharmacogenomic analyses performed in this study are summarized by best overall 
treatment response in Table 4. Pharmacodynamic and pharmacokinetic results are only reported for 
patients treated with gedatolisib, as the PF-04691502 arms were stopped early for safety reasons. 
Changes in glucose homeostasis consistent with PI3K blockade were observed following 
administration of gedatolisib. Increases in blood glucose levels were observed on day 15 of cycle 1, 
generally peaking in cycle 2 (gedatolisib/putative PI3K-basal arm) and cycle 3 (gedatolisib/putative 
PI3K-activated arm). Corresponding changes in insulin levels also were noted, lasting through cycle 4 
(data not shown). 
 
Table 4. 
 
Table 4. 
Genetic biomarker analysis and best overall response in evaluable patients treated with 
gedatolisib. 
Parameter Best overall 
response 
Gedatolisib 
(putative 
PI3K basal; 
stathmin 
low) 
n = 20 
Gedatolisib 
(putative 
PI3K 
activated; 
stathmin 
high) 
n = 18 
Gedatolisib 
(putative PI3K 
activated + basal) 
n = 38 
KRAS mutation n 20 17 37 
 Positive, n (%) PR 2 (10) 0 2 (5) 
PD 2 (10) 0 2 (5) 
Indeterminate 0 1 (6) 1 (3) 
 Negative, n (%) CR 0 1 (6) 1 (3) 
PR 1 (5) 2 (11) 3 (8) 
Stable 
disease ≥ 16 weeks 
8 (40) 0 8 (21) 
Stable 
disease < 16 weeks 
3 (15) 3 (17) 6 (16) 
PD 4 (20) 8 (44) 12 (32) 
Indeterminate 0 2 (11) 2 (5) 
PIK3CA amplification n 11 14 25 
 Amplified, n (%) PD 0 1 (6) 1 (3) 
 Non-amplified, n (%) CR 0 1 (6) 1 (3) 
PR 2 (10) 1 (6) 3 (8) 
Stable 
disease ≥ 16 weeks 
3 (15) 1 (6) 4 (11) 
Stable 
disease < 16 weeks 
1 (5) 3 (17) 4 (11) 
PD 5 (25) 6 (33) 11 (29) 
Indeterminate 0 1 (6) 1 (3) 
Abbreviation: Cr, complete response; PD, progressive disease; Pl3K, phosphatidylinositol 3-
kinases; PR, partial response. 
 
 
 
 
 
The pharmacokinetic profiles of gedatolisib following a single, intravenous 154-mg dose (day 1 of 
cycle 1) were comparable in the putative PI3K-basal and PI3K-activated arms (Supplementary Fig. 
S1). In addition, the pharmacokinetic profiles observed with gedatolisib in Japanese patients were 
consistent with those observed in Western patients, with the exception of one patient who had an 
approximately two-fold higher area under the serum concentration–time curve from 0 extrapolated 
to infinity (AUCinf) compared with the other two patients treated in the 154-mg dose group. The 
terminal elimination half-life of gedatolisib was determined to be approximately 34 to 35 h and the 
systemic clearance 10 L/h (Supplementary Table S2). 
 
4. Discussion 
This phase II study investigated the safety and efficacy of two different PI3K/mTOR inhibitors, PF-
04691502 and gedatolisib, in patients with recurrent endometrial cancer, and evaluated their safety 
and pharmacokinetics in Japanese patients. 
 
PF-04691502 was administered orally on a daily basis. The starting dose was based on phase I 
studies previously conducted in adult patients with advanced solid tumors, which included men and 
women. Four of the 18 patients who received PF-04691502 in this study developed treatment-
related pneumonitis. Non-infectious pneumonitis is a known class effect for mTOR inhibitors, which 
has been observed in ~ 30% of treated patients in retrospective studies [16]; [17] ;  [18]. Further, 
grade 3 skin toxicity was noted in 50% (n = 7) of treated patients in a phase IB/II (B1271003) study of 
PF-04691502 plus letrozole conducted in 14 women with endocrine receptor (ER)-positive, human 
epidermal growth factor receptor 2 (HER2)-negative breast cancer [19]. The severity of these 
pulmonary and skin toxicities contributed to the decision to discontinue patient enrollment to the 
PF-04691502 arms of this study and, subsequently, to terminate development of this molecule. 
 
Gedatolisib is a potent dual PI3K/mTOR inhibitor administered intravenously weekly. The rate of 
grade 3–4 AEs considered by the investigators related to treatment with gedatolisib in this study was 
generally comparable to or lower than that observed with other PI3K, mTOR, or dual PI3K/mTOR 
inhibitors such as apitolisib (GDC-0980) or pilarasilib (XL-147) [20]; [21] ;  [22]. Grade 3–4 treatment-
related AEs reported for apitolisib included hyperglycemia (46%), rash (30%), colitis (5%), and 
pneumonitis (4%); and for pilarasilib, rash (9%), diarrhea (4.5%), and increased alanine 
aminotransferase levels (4.5%) [21] ;  [22]. 
 
The 16% ORR observed with gedatolisib in each patient group studied was slightly higher than the 
ORRs reported with other dual inhibitors in similar patient populations [21] ;  [22]. The median PFS 
(108 days; 95% CI: 62–149) observed with gedatolisib was comparable to that reported with other 
agents in this setting [21] ;  [22]. An unconfirmed ORR of 9% and median PFS of 3.5 (95% CI: 2.7–3.7) 
months were observed for apitolisib [21]. A 6% ORR was reported for pilarasilib in patients who had 
received one prior regimen and 0% in those with two prior regimens. PFS > 6 months for pilarasilib-
treated patients was 11.9%, mostly in the one-prior-regimen group [22]. Additionally, single-agent 
studies of other mTOR or PI3K inhibitors in second- or third-line recurrent endometrial cancer 
showed low response rates, with no CRs and few PRs (0–9%), along with stable disease lasting ≥ 8–
12 weeks in generally < 35% of patients [20]. 
 
The changes observed in this study in metabolic biomarkers indicate that gedatolisib affected 
glucose transport and/or metabolism, resulting in increased glucose levels and providing evidence of 
pharmacodynamics effects of gedatolisib in treated patients. 
 
Prior reports had suggested that stathmin protein levels may correlate with deregulated PI3K 
signaling in cancers of the endometrium, breast, and other organs [9]; [10] ;  [11], and therefore 
response to PI3K inhibitors such as gedatolisib may be predicted by observation of higher stathmin 
protein levels. However, stathmin protein and RNA profiles do not always correlate precisely with 
genetic alterations in PI3K components or response to treatment. Further, different types of 
pathway alterations may promote different PI3K activation levels or have different effects on overall 
signaling [11]. The current study was designed to test the hypothesis that patients with high 
stathmin protein IHC scores in FFPE tumor tissues, as a biomarker for PI3K activation, would respond 
better to PI3K/mTOR inhibition. The study results do not support this hypothesis, suggesting that 
stathmin protein levels may not be correlated with tumor dependence on the PI3K pathway. It is 
recognized that the reliability of IHC scoring might have been limited by its subjective nature 
(pathologist assessment of staining intensity in tumor tissues). However, when stathmin expression 
re-scoring took place mid-way through the study, only one patient receiving gedatolisib required re-
categorization for stathmin status. 
 
This study demonstrated that gedatolisib has a manageable toxicity profile and is active as a single 
agent in patients with advanced endometrial cancer. Nonetheless, this study was terminated early, 
before patient enrollment in stage 2, following a strategic decision based on the lack of sufficient 
efficacy of gedatolisib in patients with stathmin-high/putative PI3K–activated tumors, which 
disproved the initial hypothesis. Gedatolisib appears to have activity in stathmin-low cancers and 
may be of benefit in selected patient populations; an appropriate biomarker to direct gedatolisib 
therapy was not confirmed in this study. 
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